XML 53 R30.htm IDEA: XBRL DOCUMENT
v3.25.1

Shareholders’ Equity (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Shareholders’ Equity [Abstract] |
Schedule of Share Capital | The share capital as of December 31, 2024 and 2023, is composed of as follows:
|  | Number of shares |
|  | Authorized |  |  | Issued and outstanding |
|  | December 31, 2024 |  |  | December 31, 2023 |  |  | December 31, 2024 |  |  | December 31, 2023 |
Ordinary shares, NIS 0.01 par value |  |  | 50,000,000 |  |  |  | 50,000,000 |  |  |  | 707,463 |  |  |  | 254,843 |
Schedule of Options Activity | Below is a summary of the Company’s options activity and related information with respect to options granted to employees during the years ended December 31, 2024 and 2023:
|  | Year ended December 31, |  |  | Year ended December 31, |
|  | 2024 |  |  | 2023 |
|  | Amount of options |  |  | Weighted average exercise price |  |  | Amount of options |  |  | Weighted average exercise price |
Outstanding - beginning of the year |  |  | 18,184 |  |  | $ | 62.16 |  |  |  | 12,353 |  |  | $ | 45.04 |
Granted |  |  | **4,187 |  |  | $ | 21.76 |  |  |  | *5,894 |  |  | $ | 97.92 |
Exercised |  |  | - |  |  | $ | - |  |  |  | - |  |  | $ | - |
Expired or forfeited |  |  | (62 | ) |  | $ | 105.60 |  |  |  | (62 | ) |  | $ | 53.12 |
Outstanding - end of the year |  |  | 22,309 |  |  | $ | 54.48 |  |  |  | 18,184 |  |  | $ | 62.16 |
Exercisable at end of year |  |  | 18,082 |  |  | $ | 46.56 |  |  |  | 11,114 |  |  | $ | 48.96 |
| * | Including the grant of 1,500 options to purchase up to 1,500 ordinary shares to directors, as approved by the Company’s shareholders on November 30, 2023, with an exercise price of $105.60 per share. The options will expire at the earlier of (i) ten years from the date of grant or (ii) 90 days following a termination of employment or service. The fair value of each option as of the grant date was $9.60, determined using the Black-Scholes option pricing model and the total expenses of $15 thousand will be expensed over the option vesting periods of three years.
| ** | Including the grant of 1,250 options to purchase up to 1,250 ordinary shares to the Company’s Chief Executive Officer and Chief Scientific Officer, as approved by the Company’s shareholders on September 26, 2024, with an exercise price of $34.40 per share. The options will expire at the earlier of (i) ten years from the date of grant or (ii) 90 days following a termination of employment or service. The fair value of each option as of the grant date was $15.60, determined using the Black-Scholes option pricing model and the total expenses of $19 thousand will be expensed over the option vesting periods of three years.
Schedule of weighted-Average Assumptions | The following weighted-average assumptions were used in determining the most recent fair values of stock options using the Black-Scholes valuation model:
|  | 2024 |
Expected dividend yield |  |  | 0 | %
Expected stock price volatility |  |  | 55.0 | %
Risk free interest rate |  |  | 4.10 | %
Expected life of options |  |  | 6.25 |
| * | Including the grant of 1,500 options to purchase up to 1,500 ordinary shares to directors, as approved by the Company’s shareholders on November 30, 2023, with an exercise price of $105.60 per share. The options will expire at the earlier of (i) ten years from the date of grant or (ii) 90 days following a termination of employment or service. The fair value of each option as of the grant date was $9.60, determined using the Black-Scholes option pricing model and the total expenses of $15 thousand will be expensed over the option vesting periods of three years.
| ** | Including the grant of 1,250 options to purchase up to 1,250 ordinary shares to the Company’s Chief Executive Officer and Chief Scientific Officer, as approved by the Company’s shareholders on September 26, 2024, with an exercise price of $34.40 per share. The options will expire at the earlier of (i) ten years from the date of grant or (ii) 90 days following a termination of employment or service. The fair value of each option as of the grant date was $15.60, determined using the Black-Scholes option pricing model and the total expenses of $19 thousand will be expensed over the option vesting periods of three years.
Schedule of Options to Consultants | The Company’s outstanding options to consultants as of December 31, 2024 were as follows:
Issuance date |  | In connection with |  |  | No. of options issued |  | Exercise price |  |  | No. of options exercisable |
2015 |  | Rendered services |  |  |  | 1,383 |  | $ |  | 0.24 |  |  |  | 1,383 |
2017 |  | Rendered services |  |  |  | 461 |  | $ |  | 0.24 |  |  |  | 461 |
2021 |  | Rendered services |  |  |  | 863 |  | $ |  | 0.24-$180.00 |  |  |  | 863 |
2023* |  | Rendered services |  |  |  | 1,250 |  | $ |  | 43.68 |  |  |  | 555 |
| * | On April 27, 2023, the Company’s Board of Directors approved the additional grant of options to purchase up to 1,250 ordinary shares to a consultant, with an exercise price of $43.68 per share. The options will expire at the earlier of (i) ten years from the date of grant or (ii) 90 days following a termination of services. The fair value of each option as of the grant date was $20.80, determined using the Black-Scholes option pricing model and the total expenses of $26 thousand will be expensed over the option vesting periods of three years.
Schedule of Share-Based Compensation Expenses | The share-based compensation expenses are recognized in the following line items in the consolidated statements of comprehensive loss in the years ended:
|  | December 31 |
|  | 2024 |  |  | 2023 |  |  | 2022 |
|  | U.S. dollars in thousands |
Research and development expenses |  |  | 80 |  |  |  | 83 |  |  |  | 180 |
Sales and marketing expenses |  |  | 49 |  |  |  | 61 |  |  |  | 401 |
General and administrative expenses |  |  | 53 |  |  |  | 97 |  |  |  | 209 |
|  |  | 182 |  |  |  | 241 |  |  |  | 790 |
Schedule of Issuance of Equity Warrants to Investors and Associate | Equity Warrants to investors and associated with the IPO and follow on fund raising, as of December 31, 2024:
Number of warrants/ options |  |  | Issuance date |  | Exercise price |  |  | Exercise ratio |  | Expiration date |  | Notes
| 98,261 |  |  | September 13, 2022 |  | $ | 160.00 |  |  | Each warrant is exercisable into 1 ordinary share |  | 5 years following the issuance date |  | Registered for trading (*)
| 2,344 |  |  | September 15, 2022 |  | $ | 424.80 |  |  | Each warrant is exercisable into 1 ordinary share |  | 5 years following the issuance date |  | Owned by underwriter
| 295 |  |  | September 15, 2022 |  | $ | 338.40 |  |  | Each warrant is exercisable into 1 ordinary share |  | 10 years following the issuance date |  | Owned by the legal advisor
| 205,500 |  |  | November 27, 2024 |  | $ | 10.00 | (**) |  | Each warrant is exercisable into 1 ordinary share |  | 5 years following the issuance date |  | Owned by an investor
| 78,000 |  |  | November 27, 2024 |  | $ | 0.0004 |  |  | Each pre funded warrant is exercisable into 1 ordinary share |  | Until exercised in full |  | Owned by an investor
(*) | The warrants are exercisable at any time after their original issuance and at any time up to the date that is five years after their original issuance. The warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and, at any time a registration statement registering the issuance of the ordinary shares underlying the warrants under the Securities Act of 1933, as amended, is effective and available for the issuance of such shares, by payment in full in immediately available funds for the number of ordinary shares purchased upon such exercise.
The exercise price per whole ordinary share purchasable upon exercise of the warrants $320.00 per share (the “Initial Exercise Price”). The exercise price is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting ordinary shares and also upon any distributions of assets, including cash, stock or other property to the Company’s shareholders. Subject to certain exemptions outlined in the warrant, for a period until two years from the date of issuance of the warrant, if the Company shall sell, enter into an agreement to sell and subsequently sells, or grant any option to purchase, or sell, enter into an agreement to sell and subsequently sells, or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition the subsequently closes) any ordinary shares or convertible security, at an effective price per share less than the exercise price of the warrant then in effect, the exercise price of the warrant shall be reduced to equal the effective price per share in such Dilutive Issuance; provided, however, that in no event shall the exercise price of the warrant be reduced to an exercise price lower than 50% of the Initial Exercise Price. On the date that is 90 calendar days immediately following the initial issuance date of the warrants, the exercise price of the warrants will adjust (the “Reset Price”), provided that such value is less than the exercise price in effect on that date. The Reset Price is equal to the greater of (a) 50% of the Initial Exercise Price of the warrants on the issuance date or (b) 100% of the lowest volume weighted average price per ordinary share occurring on any day between the initial exercise date of the warrants and 90 calendar days following the issuance date of the warrants. The lowest Reset Price is $160.00, which is 50% of the Initial Exercise Price.
(**) | On January 30, 2025, the exercise price of the warrants pursuant to a November 2024 private placement was adjusted to $4.00 per share following the closing of an additional offering.
Schedule of Weighted Average Number of Ordinary Shares and Pre-funded Warrants | Loss per share has been calculated using the weighted average number of ordinary shares and pre-funded warrants in issue during the relevant financial periods, the weighted average number of equity shares in issue and profit for the period as follows:
|  | Year ended December 31, 2024 |  |  | Year ended December 31, 2023 |  |  | Year ended December 31, 2022 |
Loss for the period |  |  | (7,879 | ) |  |  | (7,814 | ) |  |  | (6,496 | )
Total number of ordinary shares and pre-funded warrants |  |  | 785,464 |  |  |  | 254,843 |  |  |  | 188,121 |
Weighted average number of ordinary shares and pre-funded warrants |  |  | 325,690 |  |  |  | 202,515 |  |  |  | 153,465 |
Basic and diluted loss per share |  |  | (24.2 | ) |  |  | (38.4 | ) |  |  | (42.4 | )

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the change in Issuance of equity warrants to investors and associat. + References No definition available. + Details
Name: | wlds_ScheduleOfIssuanceOfEquityWarrantsToInvestorsAndAssociatTableTextBlock
Namespace Prefix: | wlds_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of stock options issued to consultants. + References No definition available. + Details
Name: | wlds_ScheduleOfOptionsToConsultantsTableTextBlock
Namespace Prefix: | wlds_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration